CBS News reported today that the FDA received two death reports in recent months involving products claiming to be retatrutide — one in July, one in September, both cardiac arrest, both tied to black-market supply, one involving vials a nurse sold from an online vendor. The FDA has not verified either report, and a report is not proof of cause. Eli Lilly says neither case involved its clinical trials. That distinction — trial drug vs. mystery vial wearing its name — is the whole argument of the post below.
A national health investigation published this week tells the stories of people who say experimental peptides wrecked months of their lives. A lifter who bought BPC-157 from a research-only website and spent months dealing with crushing fatigue, anxiety, and muscle twitching. A 46-year-old who took BPC-157 together with TB-4 — the combination sold online as the “Wolverine Stack” — and got migraines and one-sided facial numbness that lasted about two months. A school worker who combined BPC-157 with retatrutide for weight loss and stopped when the pain started.
I sell peptides for a living, so let me be careful and clear about what this story is and isn’t.
What it is: a reminder that these are unapproved compounds with no completed human trials behind them. BPC-157’s reputation is built on animal studies and anecdotes. There is no human trial that establishes it is safe, and none that establishes it works. When an influencer calls it “super safe,” that is a marketing claim, not a scientific one. The FDA’s adverse-event database contains hospitalization reports from people taking BPC-157. That database is voluntary and unverified — a report is not proof a product caused the harm — but “unproven” is not the same as “made up,” and the honest move is to take the reports seriously instead of waving them away.
What it isn’t: proof that every bad outcome came from the molecule itself. Read the cases closely and a second pattern shows up. The products came from anonymous online vendors selling vials labeled for laboratory research only. Nobody in these stories could show a verified test report for the vial they actually used — what was in it, at what purity, made where. When a vial’s contents are unknown, you cannot separate “this compound hurt me” from “this bottle wasn’t what the label said.” That uncertainty is not a defense of the gray market. It is an indictment of it.
That is the part of this debate that matters most to me, because it is the part a seller can actually do something about. Third-party testing with a named lab. A lot number on the vial that matches the report. A verification link a buyer can check before they pay, not a screenshot of a certificate that could belong to any batch, from any year. My Tesamorelin page carries exactly that — a Freedom Diagnostics report, 99.70% purity, searchable by its verification code. Every seller in this space should be held to that standard, including me, including on the batches still waiting for their reports.
The policy fight behind the story is real, too. This summer an FDA advisory panel voted to move BPC-157 and several other peptides toward legal pharmacy compounding, over the objections of FDA scientists who said the human evidence isn’t there yet. Both sides in that fight claim to be protecting patients. The stories in this week’s investigation are what “not enough evidence” looks like when it has a face.
So here is my honest grade on the state of things: the enthusiasm is ahead of the data, the loudest promoters are ahead of the evidence, and too many sellers are asking buyers to trust a label instead of showing them a test. If a compound has no human trials, say so. If a batch has no verified COA, don’t sell it as if it does. And if someone reports they were harmed, the answer is investigation — not mockery, and not silence.
Read the trial before you buy the vial. This week, there is no trial to read — and that is exactly the point.
Research use only. Not medical advice.
A Billion-Dollar Fight Over One Word: “Alpha”